Phathom Pharmaceuticals Inc Aktie News

Einleitung der registrierenden Phase‑3‑Studie von VOQUEZNA® (vonoprazan) zur bedarfsorientierten (PRN) Behandlung der Non‑Erosive Reflux Disease (NERD) baut auf zuvor berichteten positiven Phase‑2‑Daten auf. Topline-Ergebnisse werden im ersten Quartal 2028 erwartet. pHalcon‑NERD‑302, wenn erfolgreich, soll einen möglichen VOQUEZNA-Zulassungserweiterungsantrag unterstützen, um die bedarfsorienti...

LOS ANGELES--(BUSINESS WIRE)---- $PHAT--PHAT-Anleger haben Gelegenheit, sich mit SBS Law der Betrugsuntersuchung gegen Phathom Pharmaceuticals, Inc. anzuschließen.

FLORHAM PARK, N.J., 30. Juli 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), ein biopharmazeutisches Unternehmen, das sich auf die Kommerzialisierung und Entwicklung neuartiger Behandlungen für Gastrointestinalerkrankungen (GI) konzentriert, berichtete heute die Finanzergebnisse für das zum 30. Juni 2026 endende zweite Quartal und gab ein Geschäftsupdate.

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments fo...

FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June:

FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today highlighted the growing body of clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA® (vonoprazan), at Digestive Disease Week (DDW) 2026, he...

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois.